Vaxcyte 

Vaxcyte 

Yahoo Finance • 7 days ago

Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers

Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses. Continue Reading... Full story

Yahoo Finance • 7 days ago

Premarket movers: Constellation, Zscaler rise while Nike falls

Investing.com - U.S. stock futures edged higher on Tuesday after the Nasdaq Composite closed at a record high, as a selloff in global bond yields eased and oil prices dipped on hopes for renewed Gulf supply flows. Before you buy NVIDIA: o... Full story

Yahoo Finance • 7 days ago

Vaxcyte stock falls on $1B dual offering launch

Investing.com -- Vaxcyte Inc (NASDAQ:PCVX) shares fell 3.3% in after-hours trading Monday following the company's announcement of dual public offerings totaling $1 billion. Before you buy NVIDIA: our AI model's stock picks are beating the... Full story

Yahoo Finance • 8 days ago

Nvidia, Intel, Micron, XP Inc., PTC, Vaxcyte, Western Digital, and More Stocks That Explain Today’s Market

Intel falls as Elon Musk confirms Taiwan Semiconductor Manufacturing is in talks with Musk’s chip venture Terafab. Continue Reading... Full story

Yahoo Finance • 8 days ago

Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says. Continue Reading... Full story

Yahoo Finance • 8 days ago

Vaxcyte Stock Spikes 35% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says. Continue Reading... Full story

Yahoo Finance • 8 days ago

Vaxcyte jumps on phase 3 data for pneumonia vaccine VAX-31

[Pneumococcal vaccine in a vial, immunization and treatment of infection] Kittisak Kaewchalun /iStock via Getty Images * Vaxcyte (PCVX [https://seekingalpha.com/symbol/PCVX]) is up ~32% in Monday morning trading after reporting phase 3... Full story

Yahoo Finance • 8 days ago

Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study

Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck. Continue Reading... Full story

Yahoo Finance • 21 days ago

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

Clinical readouts are among the most important catalysts for biotechnology stocks, as study results can materially shift investor expectations about a drug candidate's efficacy, safety, regulatory prospects and commercial potential. Positi... Full story

Yahoo Finance • last month

Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing

President and CFO Andrew Guggenhime reported the disposition of 2,705 shares of Vaxcyte, Inc. (NASDAQ:PCVX), according to a recent SEC Form 4 filing. Transaction summary Metric Value Transaction value ~$165,492 Shares sold (directly held... Full story

Yahoo Finance • last month

A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know

Jim Wassil, Chief Operating Officer of Vaxcyte, Inc. (NASDAQ:PCVX), reported the sale of 6,182 shares of common stock on August 31 and September 1, totaling $378,000, according to an SEC Form 4 filing. Transaction summary Metric Value Tr... Full story

Yahoo Finance • last month

Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm

Grant Pickering, the chief executive officer of Vaxcyte, Inc. (NASDAQ:PCVX), disposed of 6,289 shares of common stock in a non-discretionary transaction, according to an SEC Form 4 filing. Transaction summary Metric Value Shares sold 6,2... Full story

Yahoo Finance • last month

Vaxcyte narrows timing for pivotal VAX-31 data to late October

[Pneumococcal pneumonia, medical concept] Dr_Microbe/iStock via Getty Images Vaxcyte (PCVX [https://seekingalpha.com/symbol/PCVX]) said it expects to report topline results from a pivotal Phase 3 trial of its pneumococcal vaccine candidat... Full story

Yahoo Finance • last month

The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble

On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage... Full story

Yahoo Finance • 2 months ago

If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone

Quick Read Baupost dumped all 800,000 PCVX shares and 893,126 WTW shares by June 30, weeks before retail investors learned Klarman had held either. 13F filings run 45 days stale, so retail investors who copied Klarman's disclosed PCVX sta... Full story

Yahoo Finance • 3 months ago

Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following in... Full story

Yahoo Finance • 4 months ago

Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 2, Vaxcyte, Inc. (NASDAQ:PCVX) dosed the first participant in its Phase 1 first-in-human clinical trial of VAX-A1. VAX-A1... Full story

Yahoo Finance • 4 months ago

Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 10 best mid-cap stocks that could double your money. On June 3, Vaxcyte Inc. (NASDAQ:PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1. Thi... Full story

Yahoo Finance • 4 months ago

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

Pivotal bioVenture Partners Investment Advisor increased its position in Trevi Therapeutics(NASDAQ:TRVI) during the first quarter, acquiring 296,944 shares in an estimated $3.32 million trade based on average quarterly pricing, according t... Full story

Yahoo Finance • 5 months ago

How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study. Continue Reading... Full story